

810

811 3.2.1.6.8 *Impurities*

812 3.2.1.6.8.1 Related substances (organic impurities)

813 Monographs should include tests and acceptance criteria for impurities that are likely to
814 occur in substances used in approved medicinal products, insofar as the necessary
815 information and samples (substance and impurities) are available from the producers.

816 Where the required information and samples have not been provided to the
817 pharmacopoeia for a substance synthesized by a given method, the monograph will not
818 necessarily cover the corresponding impurity profile.

819

820 Monographs on organic chemicals usually have a test entitled “Related substances” (or a
821 test with equivalent purpose under a different title), designed to control related organic
822 impurities. Impurities to be controlled include: intermediates and by-products of
823 synthesis, co-extracted substances in products of natural origin, degradation products.

824

825 Where the counter-ion of an active substance is formed from a lower organic acid, a test
826 for related substances of the organic moiety is usually not considered necessary (for
827 example, magnesium lactate used as a source of magnesium).

828

829 **Acceptance criteria**

830 Monographs on active pharmaceutical ingredient should take account of the principles
831 and thresholds for control of impurities as defined in ICH guideline Q3A (R2). Justified
832 deviations from this should be explicitly stated. Products of fermentation and semi-
833 synthetic products derived therefrom, should be limited applying the same principles but
834 be covered by thresholds considered appropriate for these products. The same principle
835 applies to excipients.

836

837 Monographs should include acceptance criteria for:

838

- each specified impurity;

839 • unspecified impurities, normally set at the ICH Q3A (R2) identification threshold
840 where applicable;

841 • the total of impurities (or a limit for the total of impurities other than a number of
842 identified specified impurities) above the reporting threshold/disregard limit.

843

844 Typically, the reporting threshold/disregard limit for substances covered by a monograph
845 is set in accordance with the reporting threshold given by ICH Q3A (R2) where
846 applicable.

847

848 The acceptance criteria for specified impurities take account of both:

849 • qualification data, where applicable, the limit being set at a level not greater than
850 that at which the impurity is qualified;

851 • batch analysis data, the acceptance criteria being set to take account of normal
852 production; data is provided by the producer for typical batches and checked
853 during elaboration of the monograph on not fewer than 3 batches.

854

855 All decisions on impurity acceptance criteria should be based on the real impurity content
856 (meaning after application of correction factors (CF)) in representative batches examined.

857 Impurities need to be specified and located appropriately in the chromatogram if the
858 reported batch values for an impurity are:

859 • above the applicable limit for unspecified impurities before correction and cross
860 the limit downwards when corrected (overestimation, $CF < 1$), or

861 • below the limit for unspecified impurities before correction and cross this limit
862 upwards when corrected (underestimation, $CF > 1$).

863

864 No correction factor will be given if the reported batch values for an impurity are:

865 • below the applicable limit for unspecified impurities before correction and below
866 the disregard limit after correction.

867

868 **Enantiomeric purity.** A monograph on an enantiomer includes wherever possible a test
869 for enantiomeric purity by liquid chromatography (LC) using chiral separation to limit
870 the presence of the unwanted enantiomer.

871

872 **Unusually potent or toxic impurities.** In addition to the above mentioned requirements,
873 impurities that are unusually potent or produce toxic or unexpected pharmacological
874 effects, need to be specifically considered. In this context requirements for genotoxic
875 impurities have to be followed (to be completed after adoption of ICH M7).

876

877 **Analytical methods for determination of organic impurities**

878 The most common and preferred method for control of organic impurities is LC; gas
879 chromatography (GC) or capillary electrophoresis (CE) may be the preferred method in
880 some instances. Thin-layer chromatography (TLC) should be reserved for control of
881 specific impurities that cannot conveniently be controlled by LC or GC.

882

883 **Monographs frequently have to be designed to cover different impurity profiles because**
884 **of the use of different synthetic routes and purification procedures by producers. The**
885 **usual practice is to include a general LC test, supplemented where necessary by other**
886 **tests (LC, GC, CE, TLC, or other techniques) for specific impurities. It is, however,**
887 **becoming increasingly impractical in some cases to design a single general test and in**
888 **such cases more than one general test is included and the scope of the different tests is**
889 **defined in the tests themselves by cross-reference to the impurities covered (e.g. in an**
890 **Impurities section).**

891

892 For pharmacopoeial purposes the objective of a purity test using a separation method will
893 usually be the control of impurities derived from one or more known manufacturing
894 processes and decomposition routes. However, the experimental conditions are chosen
895 for the test, especially the detection system, so as not to make it unnecessarily narrow in
896 scope. Chromatographic purity tests may often be the best means of providing a general

897 screening of organic impurities derived from new methods of manufacture or accidental
898 contamination.

899

900 Monographs should provide a reliable means of locating all specified impurities on the
901 chromatogram. Identification of unspecified impurities is necessary if a correction factor
902 is to be applied. Peaks may be located using:

- 903 • a reference standard for each impurity;
- 904 • a reference standard containing some or all of the specified impurities, provided
905 with a chromatogram;
- 906 • location by relative retention is not generally considered sufficient for
907 pharmacopoeial purposes, notably for gradient elution.

908

909 General considerations applying to separation techniques:

- 910 • high concentrations/loadings are normally used since the symmetry of the
911 principal peak or shape of the spot is not critical in impurity testing so long as
912 there is no interference. When using an external standard in quantitative
913 determinations the response of the principal peak need not be in the linear range
914 of the detector;
- 915 • in general tests for related substances, the substance to be examined should not to
916 be chemically modified (e.g. derivatization) before purity testing since the
917 impurity pattern may be modified;
- 918 • similarly, extraction of the free base or acid prior to impurity testing is to be
919 avoided.

920 3.2.1.6.8.1.1 Thin-layer chromatography

921 TLC methods should only be used for control of a specified impurity and where liquid
922 chromatography, gas chromatography or capillary electrophoresis methods are
923 inappropriate (usually due to a lack of a suitable detection system).

924

925 Commercially available precoated plates are to be used; the trade name of the plate found
926 suitable should be made available to the public but leaving some flexibility to the user for
927 using another brand of material if demonstrated to be suitable. The monograph describes
928 the type of plate (not the commercial name) and includes system suitability criteria for
929 verification of the separation capacity and of the sensitivity. Often the substances that
930 would be best suited for a system suitability test will not be readily available individually;
931 a sample of the substance to be examined containing them as contaminants or even a
932 deliberately spiked sample may then be prescribed. Permissible variations to the different
933 parameters are indicated in a general chapter on *Chromatography*.

934
935 If any pretreatment is required or if the chromatography is carried out in unsaturated
936 conditions for the satisfactory conduct of the test, then this information is included in the
937 text of the monograph (especially applicable to the use of reverse-phase plates).

938 One or more dilutions of the substance to be examined will often prove adequate for
939 reference purposes, provided the impurities to be compared exhibit a similar behaviour
940 under the chosen chromatographic conditions. This implies that the spots to be compared
941 are sufficiently close in R_f value to minimize errors introduced by different diffusion of
942 the substances during their migration. Otherwise, reference solutions containing the
943 specified impurities are to be employed.

944 3.2.1.6.8.1.2 Liquid chromatography

945 Defining the appropriate chromatographic system will often be one of the major problems
946 to be dealt with in elaborating a pharmacopoeial purity test based on LC. The matter is
947 further complicated by the existence of numerous variants of stationary phases, especially
948 amongst the chemically bonded reverse-phase materials for which not only brand-to-
949 brand but occasionally also batch-to-batch variations occur that can influence a given
950 separation. During the validation of the method several types of stationary phase should
951 be tested and the brand names of materials found to be suitable should be made available
952 to the public through appropriate means but leaving some flexibility to the user for using
953 another brand of material if demonstrated to be suitable.

954

955 In describing the chromatographic system, mention is made of the column dimensions
956 (length and internal diameter), nature of the stationary phase (in detail) and its particle
957 size including any steps to prepare or pretreat it, composition and flow rate of the mobile
958 phase including elution programme (if any), column temperature (if differing from
959 ambient or especially if thermostated), method of injection (if important), injection
960 volume and method of detection. Permissible variations to the different parameters are
961 indicated in a general chapter on *Chromatography* or in the individual monographs.

962

963 Test and reference solutions are wherever possible prepared using the mobile phase as the
964 solvent in order to minimize peak anomalies.

965

966 For the sake of simplicity and reproducibility, isocratic elution is to be preferred. If the
967 chromatography is not carried out at normal room temperature (15 °C to 25 °C), the
968 temperature is specified (≥ 30 °C).

969

970 When a gradient system is described, all necessary parameters are clearly given, e.g.
971 composition of mobile phases, equilibrium conditions, gradient conditions (linear or step),
972 etc.

973

974 An important parameter to be considered in gradient elution is the volume between the
975 solvent mixing chamber and the head of the column, usually referred to as the dwell
976 volume, D (other terms employed include: effective system delay volume, dead volume
977 and delay volume). A method for the determination of dwell volume can be indicated in a
978 general chapter on *Chromatography*. Large differences in dwell volume from one
979 pumping system to another will result in differences in elution of peaks. The greatest
980 effect of differing dwell volumes on retention times is for those substances that are not
981 strongly retained. Thus, gradient systems should be conceived in such a way that analytes
982 are not eluted at or near the beginning of a gradient. It is best if less strongly retained
983 components are eluted with an initial isocratic phase followed by a gradient for elution of
984 the more strongly retained analytes. The effect of differences in dwell volumes is then
985 minimized. In addition, an initial isocratic phase allows correcting for marked differences

986 in dwell volume from one gradient pumping system to another. The dwell volume of the
987 instruments used during development of the method is given in the monograph or made
988 available to the public by other suitable means (e.g. database).

989

990 The quality of water and solvents to be used should be defined.

991 3.2.1.6.8.1.2.1 *Quantification*

992 Quantification is required for limits applied to specified impurities, unspecified
993 impurities and total impurities. It is most commonly achieved using an external standard
994 and less commonly by the normalization procedure.

995

996 *External standard.* A dilution of the test solution/substance to be examined is usually
997 used as external standard. A specific external standard may also be used:

- 998 • a solution of the impurity (preferred option);
- 999 • a solution of the substance to be examined containing a known amount of the
1000 impurity.

1001

1002 Where a dilution of the substance to be examined is used as external standard, correction
1003 factors¹ for the impurities should be determined during the development of the method
1004 and indicated in the monograph only if they are outside a range of 0.8 to 1.2 and
1005 considered relevant in view of the batch results. Correction factors are normally given
1006 with only 1 decimal place. It is recommended not to apply correction factors >5 for
1007 specified impurities, but to use external standards in these cases where possible.

1008

1009 *Normalization procedure.* Quantification by the area normalization technique requires
1010 that all the solutes are known to be eluted and detected, preferably with uniform response
1011 factors, and that the detector response is linear with the concentrations employed. This
1012 should be validated. Correction factors are introduced where applicable.

¹ The correction factor is the reciprocal of the relative detector response factor (commonly referred to as *response factor*), the latter expressing the sensitivity of a detector for a given impurity relative to the substance to be examined.

1013

1014 Peaks due to solvents or reagents or arising from the mobile phase or the sample matrix,
1015 and those at or below the disregard limit, are excluded before calculating the percentage
1016 content of a substance by normalization. The disregard limit is defined as the peak area
1017 obtained with a reference solution. The corresponding numerical value (percentage
1018 compared to the test solution) is given in brackets for information.

1019 *3.2.1.6.8.1.2.2 System suitability criteria*

1020 Several system suitability criteria are to be included in the test. Requirements are given in
1021 the individual monograph and/or in general texts that are cross referred to.

1022

1023 Separation capacity. Such a criterion is necessary when separation techniques are
1024 employed for assays and tests for related substances. The following approaches are
1025 acceptable for a system suitability test for selectivity:

- 1026 • Resolution. As calculated by the formula given in a general chapter on
1027 *Chromatography* using 2 closely eluting peaks, preferably corresponding to the
1028 substance itself and a potential impurity. However, when the elution times of the
1029 2 peaks are very different, i.e. when the resolution factor is large (>5.0), it is
1030 preferable to use another impurity or another substance chemically related to the
1031 substance under study, giving a smaller resolution factor. Peaks of different
1032 heights may be used for calculation of resolution but extreme differences will
1033 compromise the usefulness of the criterion. Saturation of the peaks should be
1034 avoided.
- 1035 • Peak-to-valley ratio. Can be employed when complete separation between
1036 2 adjacent peaks cannot be achieved, i.e. when the resolution factor is less than 1.5.

1037

1038 In-situ degradation offers an alternative approach to define the suitability of the system
1039 provided that the solution of the substance can be degraded, in mild “stress” conditions
1040 within a reasonably short time, to produce decomposition products, the peaks of which
1041 can be used to determine a resolution or a peak-to-valley ratio.

1042

1043 A “spiked” or an impure substance can also be employed to define the system. This
1044 approach can be employed when it is difficult to isolate an impurity eluting close to the
1045 main peak in sufficient quantity to establish a reference substance. In this case a
1046 chromatogram can be supplied with the reference substance (for system suitability), or
1047 published with the monograph or described in the text of the test for related substances. A
1048 requirement for resolution or peak-to-valley ratio is also to be included.

1049

1050 When gradient elution is described, it is preferable to describe a system suitability
1051 requirement for each critical gradient step.

1052

1053 Sensitivity. The method should be designed to achieve sufficient sensitivity. A S/N ratio
1054 ≥ 10 at the disregard limit/reporting threshold has to be observed by the user. It may be
1055 necessary to add a specific sensitivity criterion for specified impurities, e.g. for impurities
1056 with high correction factor. Example: impurity X specified at 0.15 %, correction factor 5,
1057 general disregard limit 0.05 %. For the considered impurity X, the sensitivity of the
1058 method is sufficient if (1) a S/N ratio of minimum 10 is obtained with a 0.05 % (relative
1059 to the test solution) solution of impurity X, when impurity X is available as reagent/CRS
1060 or (2) a S/N ratio of minimum 50 is obtained with a 0.05 % solution of the active
1061 substance when impurity X is not available. Option (2) is preferred when only limited
1062 amounts of the isolated impurity are available.

1063

1064 System repeatability. A requirement for the maximum permitted relative standard
1065 deviation (calculated for a series of injections of the reference solution(s) used for
1066 quantification) is included in the monograph or given in a general text that is cross
1067 referred to.

1068

1069 Peak symmetry. A requirement for the symmetry factor (also known as the asymmetry
1070 factor or tailing factor) of the peak in the chromatogram obtained with the reference
1071 solution(s) used for quantification is included in the monograph or given in a general text
1072 that is cross referred to.

1073 3.2.1.6.8.1.3 Gas-liquid chromatography

1074 The difficulties met when defining the appropriate chromatographic system are similar in
1075 GC purity tests to those mentioned under LC although the emphasis may be on other points.
1076 In describing the chromatographic system, mention is made of essentially the same factors
1077 as mentioned under LC with appropriate variations, e.g. temperature programme (if any)
1078 instead of elution programme, injection port and detector temperatures, etc. The nature of
1079 the stationary phase, i.e. the composition of the coating material (including its
1080 concentration) and the inert support (including its particle size and any pre-treatment) are
1081 also given here in general terms but the brand names of material found to be suitable
1082 should be made available to the public through appropriate means (e.g. database or general
1083 chapter). Use of packed columns should be avoided. Permissible variations to the different
1084 parameters are indicated in a general chapter on *Chromatography*.

1085

1086 For the sake of simplicity and reproducibility isothermal operating conditions are
1087 preferred. Quantification is usually based on an internal standard technique or on the area
1088 normalization procedure.

1089 3.2.1.6.8.1.4 Capillary electrophoresis

1090 CE may be employed to separate and control a large number of impurities of vastly
1091 different polarities. It is also suitable to control the content of the unwanted enantiomer in
1092 chiral therapeutic substances.

1093

1094 For the control of impurities or assays, the use of an internal standard is recommended to
1095 achieve appropriate precision.

1096

1097 For chiral analysis, a chiral reagent is added to the running buffer. The chiral reagent
1098 should be carefully described in the monograph or as a reagent, particularly for
1099 cyclodextrin derivatives and the brand names of materials found to be suitable should be
1100 made available to the public through appropriate means (e.g. database or general chapter).

1101

1102 *Experimental parameters to be considered for inclusion in the monograph:*

- 1103 • instrumental parameters: voltage, polarity, temperature, capillary size (diameter
1104 and length – total and effective – to the detector);
- 1105 • coating material of the capillary (where applicable).(if a coated capillary is used,
1106 the trade name of the capillary found suitable during elaboration of the
1107 monograph should be made available to the public through appropriate means (e.g.
1108 database or general chapter);
- 1109 • buffer: pH, molarity, composition;
- 1110 • sample solvent;
- 1111 • separation: pole outlet, separation voltage U or current I ;
- 1112 • injection: time t , voltage U or pressure Δp ;
- 1113 • detection: wavelength, instrumentation;
- 1114 • temperature;
- 1115 • shelf-life of solutions
- 1116 • rinsing procedures (time, reagents, pressure Δp) needed to stabilize the migration
1117 times and the resolution of the peaks:
- 1118 - preconditioning of a new capillary,
- 1119 - preconditioning of the capillary before a series of measurements,
- 1120 - between-run rinsing.
- 1121
- 1122 In order to minimize the electro-osmotic flow (EOF) signal, test and reference solutions
1123 are, wherever possible, prepared using water for injections or the running buffer as the
1124 solvent.
- 1125
- 1126 It is recommended to make cross-reference to an internationally harmonized general
1127 method (see 3.2.1.10.).
- 1128 **3.2.1.6.8.2 Inorganic impurities**

1129 Inorganic impurities include reagents, ligands and catalysts, metal impurities, inorganic
1130 salts and other materials such as filter aids (where relevant).

1131

1132 Known impurities, likely to be present, are typically covered by specific tests.

1133 Metal impurities: (to be drafted after adoption of ICH Q3 D)

1134 3.2.1.6.8.3 Residual solvents

1135 Control of residual solvents is typically provided for in the pharmacopoeia by a:

- 1136 • General chapter that takes into consideration the classification and acceptable
1137 limits of the ICH Guideline Q3C;
- 1138 • General method for the identification and determination of residual solvents
1139 which contains the default methods to be applied.

1140

1141 Where the limits to be applied are in line with the general monograph, tests for residual
1142 solvents are not specifically mentioned in individual monographs since the solvents
1143 employed may vary from one manufacturer to another.

1144

1145 A test and limit for a Class 1 solvent is included in the individual monograph if it is
1146 potentially present in an approved product.

1147

1148 Tests and limits for Class 2 solvents are not included in monographs since the limit may
1149 be set using option 2 of the ICH guideline/General chapter, whereby all the ingredients of
1150 a pharmaceutical preparation are taken into account.

1151

1152 A test and limit for a Class 3 solvent is included in the individual monograph if it is
1153 potentially present in an approved product at a level higher than 0.5%.

1154 3.2.1.6.9 Foreign anions and/or cations

1155 Since strong inorganic acids and bases are widely used in syntheses, the contents of
1156 foreign anions and/or cations in a substance can be indicative of the extent to which it has
1157 been purified. They can also reveal whether contamination with closely related

1158 substances has taken place. On the other hand, the usually ionic impurities can often be
1159 removed from poorly water-soluble substances by treatment with water without
1160 necessarily removing the organic impurities. Tests for anions and cations therefore cannot
1161 replace a test for related substances in organic substances but they may constitute a useful
1162 supplement in the case of the water-soluble organic substances. For inorganic substances,
1163 which are usually prepared from other inorganics, a much broader range of tests for
1164 foreign ions are contemplated.

1165
1166 Where the introduction of tests for foreign anions in organic substances is considered
1167 then a single one, either for chlorides, sulfates or – less commonly – nitrates, will usually
1168 suffice even when several could theoretically be present. The test is then to be carried out
1169 on the most abundant anion.

1170
1171 Certain cations are stringently limited because of their toxicity or catalytic activity. They
1172 are treated separately under Heavy metals. Unless there are special reasons for limiting
1173 the presence of cations, individually or in smaller groups, in organic substances, the
1174 majority are adequately controlled via a determination of sulfated ash (see further).

1175 *3.2.1.6.10 Loss on drying*

1176 A General chapter includes sets of standard conditions that are referred to in monographs
1177 using conventional expressions. If other conditions are used, they are described in full in
1178 the monograph. Drying is carried out to constant mass, unless a drying time is specified
1179 in the monograph. When a drying time is prescribed, this should have been validated.

1180 Where a drying temperature is indicated using a single value, a tolerance of ± 2 °C is
1181 understood. For temperatures higher than 105 °C, a larger tolerance should be indicated
1182 in the monograph, if necessary. Drying in an oven at 105 °C is to be preferred when the
1183 product is sufficiently stable at that temperature. Otherwise, drying over P₂O₅ at 1.5–2.5
1184 kPa at room temperature or at a specified temperature is usually applied. It should
1185 however be remembered that organic solvents are not always easily removed (e.g.
1186 organic solvents in colchicine).

1187

1188 Generally an upper limit for loss on drying is given. If the substance is a hydrate (or
1189 solvate), upper and lower limits are indicated. Limits lower than 10 % should be given
1190 with 2 significant figures and limits of 10 % or greater should be given with 3 significant
1191 figures. The sample size is chosen to give a difference of 5–50 mg before/after drying and
1192 is indicated with 4 significant figures.

1193

1194 When only class 3 solvents are used, a test for loss on drying with a limit at 0.5% may be
1195 included to control water and residual solvents at the same time.

1196

1197 The test can be carried out on a semi-micro scale, in which case the accuracy with which
1198 the test sample is to be weighed should be specified accordingly.

1199 Thermogravimetry

1200 Loss on drying can be determined by this method when the amount of substance has to be
1201 restricted, for example to reduce exposure for the analyst or if the substance is very
1202 expensive (e.g. vincristine sulfate and vinblastine sulfate).

1203 *3.2.1.6.11 Water*

1204 *3.2.1.6.11.1 Semi-micro determination of water (Karl Fischer)*

1205 The sample size is chosen to obtain a titration volume of about 1 mL and should be given
1206 with 3 significant figures. Commercial reagents without pyridine are now used instead of
1207 *iodosulfurous reagent R*; stoichiometry and freedom from interference are to be verified
1208 (data may be provided by the supplier of the reagent for the substance in question).

1209

1210 Commercial reagents found to be suitable should be made available to the public through
1211 appropriate means (e.g. database or general chapter).

1212

1213 Limits lower than 10% should be given with 2 significant figures and limits of 10% or
1214 greater should be given with 3 significant figures.

1215

1216 Semi-micro determination is not recommended for a water content of less than 0.5%.

1217 3.2.1.6.11.2 Micro determination of water (coulometric titration)

1218 Coulometric titration is restricted to the quantitative determination of small amounts of
1219 water. The sample size is chosen to have a water content of 10 µg to 10 mg; titration of
1220 quantities of the order of 10 µg are prescribed only where the water content is very low or
1221 the sample size is limited by the cost of the substance. The sample size should be stated
1222 with 3 significant figures.

1223

1224 No detailed description is given for the composition of the electrolyte (anolyte and
1225 catholyte) reagent, as almost all laboratories use commercially available ready-to-use
1226 reagents. Commercial reagents found to be suitable should be made available to the
1227 public through appropriate means (e.g. database or general chapter).

1228

1229 Limits should be expressed with 2 significant figures.

1230 3.2.1.6.12 Sulfated ash/Residue on ignition

1231 This test is usually intended for the global determination of foreign cations present in
1232 organic substances and in those inorganic substances which themselves are volatilized
1233 under the conditions of the test. Thus the test will be of little value as a purity
1234 requirement for the majority of inorganic salts of organic substances, due to the resulting
1235 high bias.

1236

1237 The limit in a test for sulfated ash is usually set at 0.1%, unless otherwise justified. The
1238 amount of substance prescribed for the test is such that a residue corresponding to the
1239 limit will weigh not less than 1.0 mg and the prescribed mass of substance is then given
1240 with the appropriate precision (1.0 g). The use of an internationally harmonized general
1241 method (see 3.2.1.11) is recommended.

1242 3.2.1.6.13 Residue on evaporation

1243 The amount of a liquid material prescribed for the test is such that a residue
1244 corresponding to the limit will weigh at least 1.0 mg. The appropriate mass or volume of
1245 the substance will normally be in the range of 10 g to 100 g (or mL).

1246

1247 3.2.1.6.14 *Sterility*

1248 A test for sterility is prescribed wherever such control is necessary e.g. when it is known
1249 that the substance is intended for use in the manufacture of sterile dosage forms without a
1250 further appropriate sterilization procedure.

1251

1252 A cross-reference to a general method describing the test for sterility, preferably the
1253 general method internationally harmonized (see 3.2.1.11) is then included.

1254 3.2.1.6.15 *Microbiological purity*

1255 Individual monographs give acceptance criteria for microbiological quality wherever
1256 such control is necessary (total aerobic microbial count (TAMC), total combined
1257 yeasts/moulds count (TYMC), specific microorganisms).

1258

1259 Microbial examination is performed according to methods given in general chapters that
1260 will be referred to in the individual monograph. The use of an internationally harmonized
1261 method (see 3.2.1.11) is recommended.

1262 3.2.1.6.16 *Bacterial endotoxins*

1263 If the substance is offered as bacterial endotoxin-free grade, the limit and test method (if
1264 not Gel-clot method: limit test) are stated in the individual monograph. The limit is
1265 calculated in accordance with a general chapter of the pharmacopoeia unless a lower limit
1266 is justified from results from production batches or is required by the competent authority.
1267 The use of an internationally harmonized method (see 3.2.1.11) is recommended.

1268 *Abnormal toxicity*

1269 A test for abnormal toxicity may be included in some specific cases, e.g. new substances
1270 of biological origin.

3.2.1.7 *Assay*

1271 Assays are included in monographs unless:

- 1272 • all the foreseeable impurities can be detected and limited with sufficient
1273 precision;

- 1274 • certain quantitative tests, similar to assays, are carried out with sufficient
1275 precision (specific optical rotation, specific absorbance);
- 1276 • specific profiles of relevant substances such as composition of the fatty acid
1277 fraction or composition of the sterol fraction of a fat or fatty oil have been
1278 established;
- 1279 • the tests performed are sufficient to establish the quality of the substance, usually
1280 a non-active ingredient, for example ethanol and water.

1281

1282 In certain cases, more than one assay may be necessary when:

- 1283 • the substance to be examined consists of a combination of 2 parts that are not
1284 necessarily present in absolutely fixed proportions, so that the assay of only 1 of
1285 the 2 constituents does not make it possible correctly to determine the substance
1286 as a whole;
- 1287 • the results of the quantitative tests do not fully represent the therapeutic activity,
1288 in which case a biological assay is included.

1289

1290 In the case of well-defined salts, the assay of only one of the ions, preferably the
1291 pharmacologically active component, is generally considered sufficient.

1292

1293 When the identification and purity tests are sufficiently characteristic and searching, a
1294 non-specific but precise assay (as volumetric analysis) may be used rather than a specific
1295 and less precise assay (as LC).

1296

1297 Every assay method proposed is validated.

1298 3.2.1.7.1 *Ultraviolet and visible spectrophotometry*

1299 Spectrophotometric assays may be carried out directly in the ultraviolet or visible range
1300 or after a suitable chemical reaction, though the latter are less precise. Other methods
1301 (especially LC methods) are usually preferred.

1302 3.2.1.7.2 *Volumetric analysis*

1303 The amount of the substance taken for the assay is such that the final titration, using
1304 automatic titration equipment, will consume less than 10 mL – preferably between 7 and
1305 8 mL – of titrant in order to permit the use of standard titration equipment. In the case of
1306 back-titration, the fixed volume of the first titrant added is, furthermore, adequate so that
1307 the result of the assay will not be based upon a small difference of volumes.

1308

1309 Either a potentiometric end-point detection or a visual colour change indicator can be
1310 specified in the monograph. The potentiometric mode of end-point detection is applicable
1311 in almost all cases and is to be preferred. Where potentiometric detection is specified, the
1312 appropriate combination of electrodes for that purpose is, whenever useful, to be given in
1313 the text. The number of inflexion points to be evaluated is given. Exceptionally, other
1314 modes of detection are specified, such as the amperometric method. Whichever mode is
1315 used, it is known to be appropriately reproducible and preferably stoichiometrically exact.

1316 3.2.1.7.3 *Chromatography*

1317 The chromatographic methods on which assays may be based are in pharmacopoeial
1318 practice normally limited to LC and GC. Such methods require the use of a reference
1319 standard with an assigned content of the analyte. The addition of an internal standard in
1320 GC is recommended. Requirements for the maximum permitted relative standard
1321 deviation (calculated for a series of injections of the reference solution) and the symmetry
1322 factor of the analyte peak are included in the monograph or given in a general text that is
1323 cross referred to.

3.2.1.8 *Storage*

1324 Although the statements given under this heading in a monograph of the pharmacopoeia
1325 do not constitute pharmacopoeial requirements, the appropriate information to safeguard
1326 the quality of a pharmacopoeial material during storage is to be given here where
1327 appropriate.

1328

1329 The terminology used should be defined in a general text.

1330

1331 Manufacturers should be requested to provide stability data. In considering the guidance
1332 to be given in the monograph, the behaviour of the material towards exposure to
1333 atmospheric air, various degrees of humidity, different temperatures and daylight are to
1334 be taken into account.

3.2.1.9 Labelling

1335 In respect of the fact that the labelling of medicine is subject to international agreements
1336 and supranational and national regulations, the indications given under LABELLING are not
1337 exhaustive and cannot be harmonized: they may consist of mandatory statements (for
1338 example, those necessary for the application of the monograph) and other statements that
1339 may be included only as recommendations. When, for example, a starting material has to
1340 comply with additional requirements (sterility, etc.) the label states, where appropriate,
1341 that the contents of the container are suitable for that use. Furthermore, when the
1342 inclusion of certain stabilizers or other additives is authorized by the monograph, their
1343 presence will generally have to be declared on the label.

3.2.1.10 Impurities

1344 Monographs on organic chemicals should have a transparency list defining all specified
1345 impurities covered by the monograph. In addition, it may be useful to include information
1346 on other detectable impurities (impurities that are known to be detected by the
1347 monograph tests but that are not known to occur routinely in current production batches
1348 *above the identification threshold*).

1349
1350 The transparency list gives at least the chemical nomenclature of each impurity (of the
1351 base/acid where applicable). Trivial names may be included in parenthesis in the rare
1352 cases where they are considered to be informative. If the chemical structure is given,
1353 impurities are represented in a similar manner to the parent substance to make it clear that
1354 they are structurally analogous.

1355 3.2.1.11 *General methods*

1356 A number of general methods mentioned above have been harmonized by the PDG and
1357 are currently under implementation by *The International Pharmacopoeia*. Their
1358 prospective use for future monograph elaboration is encouraged.

1359

1360

1361 3.2.2 *Monographs for finished products*

1362 [as received from BP, Ph.Eur., Russian Pharmacopoeia (sterility), USP]

1363

1364 3.2.2.1 *Concept*

1365

1366 Specifications in pharmacopoeias are one facet of the overall control of the quality of
1367 medicinal products and their constituents. The monographs for finished products provide
1368 a publicly available standard that a product or a component of a product is expected to
1369 meet at any time during its period of use. Pharmacopoeial specifications are used within
1370 pharmaceutical product licensing or authorization systems and by manufacturers,
1371 suppliers, purchasers and those acting on behalf of consumers of medicinal products.

1372

1373 Before the process of writing a monograph for a finished product can begin, it is
1374 important to consider the Tests that are required to demonstrate the quality of a given
1375 pharmaceutical form; product-specific tests should be avoided, where possible. These
1376 tests should be applied consistently in monographs across all participating
1377 pharmacopoeias.

1378

1379 The format for the inclusion of tests may vary regionally. For example, certain regions
1380 specify compliance with manufacturing based testing (usually measures of the physical or
1381 physicochemical acceptability) in the specific monograph, while others incorporate these
1382 requirements in General monographs for a particular pharmaceutical form.

1383

1384